|
1
|
Pruksakorn D, Phanphaisarn A, Pongnikorn
D, Daoprasert K, Teeyakasem P, Chaiyawat P, Katruang N and
Settakorn J: Age standardized incidence rates and survival of
osteosarcoma in northern thailand. Asian Pac J Cancer Prev.
17:3455–3458. 2016.PubMed/NCBI
|
|
2
|
Aznab M and Hematti M: Evaluation of
clinical process in osteosarcoma patients treated with chemotherapy
including cisplatin, adriamycin, ifosfamide, and etoposide and
determination of the treatment sequels in a long-term 11-year
follow-up. J Cancer Res Ther. 13:291–296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
PosthumaDeBoer J, Witlox MA, Kaspers GJ
and van Royen BJ: Molecular alterations as target for therapy in
metastatic osteosarcoma: A review of literature. Clin Exp
Metastasis. 28:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Du MD, He KY, Qin G, Chen J and Li JY:
Adriamycin resistance-associated prohibitin gene inhibits
proliferation of human osteosarcoma MG63 cells by interacting with
oncogenes and tumor suppressor genes. Oncol Lett. 12:1994–2000.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yoon TM, Kim SA, Lee DH, Lee JK, Park YL,
Lee KH, Chung IJ, Joo YE and Lim SC: Livin enhances chemoresistance
in head and neck squamous cell carcinoma. Oncol Rep. 37:3667–3673.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li CJ, Cong Y, Liu XZ, Zhou X, Shi X, Wu
SJ, Zhou GX and Lu M: Research progress on the livin gene and
osteosarcomas. Asian Pac J Cancer Prev. 15:8577–8579. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hou Q, Li MY, Huang WT, Wei FF, Peng JP,
Lou MW and Qiu JG: Association between three VEGF polymorphisms and
renal cell carcinoma susceptibility: A meta-analysis. Oncotarget.
8:50061–50070. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liang L, Yue Z, Du W, Li Y, Tao H, Wang D,
Wang R, Huang Z, He N, Xie X, et al: Molecular imaging of inducible
VEGF expression and tumor progression in a breast cancer model.
Cell Physiol Biochem. 42:407–415. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yan B, Kong M, Chen S and Chen YH: VEGF
stimulation enhances Livin protein synthesis through mTOR
signaling. J Cell Biochem. 111:1114–1124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen L, Ren GS, Li F and Sun SQ:
Expression of livin and vascular endothelial growth factor in
different clinical stages of human esophageal carcinoma. World J
Gastroenterol. 14:5749–5754. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pagani E, Ruffini F, Cappellini Antonini
GC, Scoppola A, Fortes C, Marchetti P, Graziani G, D'Atri S and
Lacal PM: Placenta growth factor and neuropilin-1 collaborate in
promoting melanoma aggressiveness. Int J Oncol. 48:1581–1589. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Babkina IV, Osipov DA, Solovyov YN,
Bulycheva IV, Machak GN, Aliev MD and Kushlinsky NE: Endostatin,
placental growth factor, and fibroblast growth factors-1 and −2 in
the sera of patients with primary osteosarcomas. Bull Exp Biol Med.
148:246–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marrony S, Bassilana F, Seuwen K and
Keller H: Bone morphogenetic protein 2 induces placental growth
factor in mesenchymal stem cells. Bone. 33:426–433. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mahmoodi F and Akrami H: PlGF knockdown
decreases tumorigenicity and stemness properties of spheroid body
cells derived from gastric cancer cells. J Cell Biochem.
118:851–859. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Incio J, Tam J, Rahbari NN, Suboj P,
McManus DT, Chin SM, Vardam TD, Batista A, Babykutty S, Jung K, et
al: PlGF/VEGFR-1 signaling promotes macrophage polarization and
accelerated tumor progression in obesity. Clin Cancer Res.
22:2993–3004. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Enneking WF, Spanier SS and Goodman MA: A
system for the surgical staging of musculoskeletal sarcoma. Clin
Orthop Relat Res. 106–120. 1980.PubMed/NCBI
|
|
17
|
Kawasaki H, Altieri DC, Lu CD, Toyoda M,
Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin
predicts shorter survival rates in colorectal cancer. Cancer Res.
58:5071–5074. 1998.PubMed/NCBI
|
|
18
|
Wang YF, Shen JN, Xie XB, Wang J and Huang
G: Expression change of ezrin as a prognostic factor in primary
osteosarcoma. Med Oncol. 28 Suppl 1:S636–S643. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sampson VB, Vetter NS, Zhang W, Patil PU,
Mason RW, George E, Gorlick R and Kolb EA: Integrating mechanisms
of response and resistance against the tubulin binding agent
Eribulin in preclinical models of osteosarcoma. Oncotarget.
7:86594–86607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Horie R, Nakamura O, Yamagami Y, Mori M,
Nishimura H, Fukuoka N and Yamamoto T: Apoptosis and antitumor
effects induced by the combination of an mTOR inhibitor and an
autophagy inhibitor in human osteosarcoma MG63 cells. Int J Oncol.
48:37–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Saleem M, Qadir MI, Perveen N and Ahmad B,
Saleem U, Irshad T and Ahmad B: Inhibitors of apoptotic proteins:
New targets for anticancer therapy. Chem Biol Drug Des. 82:243–251.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu GH, Wang C and Ding ZY: Overexpression
of the truncated form of Livin reveals a complex interaction with
caspase-3. Int J Oncol. 42:2037–2045. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin X, Li HR, Lin XF, Yu ME, Tu XW, Hua
ZD, Lin M, Xu NL, Han LL and Chen YS: Silencing of Livin inhibits
tumorigenesis and metastasis via VEGF and MMPs pathway in lung
cancer. Int J Oncol. 47:657–667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhuang L, Shen LD, Li K, Yang RX, Zhang
QY, Chen Y, Gao CL, Dong C, Bi Q, Tao JN, et al: Inhibition of
livin expression suppresses cell proliferation and enhances
chemosensitivity to cisplatin in human lung adenocarcinoma cells.
Mol Med Rep. 12:547–552. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nedelcu T, Kubista B, Koller A, Sulzbacher
I, Mosberger I, Arrich F, Trieb K, Kotz R and Toma CD: Livin and
Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin
Oncol. 134:237–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guan HP, Sun JZ, Feng XL, Chen JS, Chen
FJ, Cheng XF, Liu XW and Ni B: Effects of RNA interference-mediated
knockdown of livin and survivin using monomethoxypolyethylene
glycol-chitosan nanoparticles in MG-63 osteosarcoma cells. Mol Med
Rep. 13:1821–1826. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ségaliny AI, Mohamadi A, Dizier B,
Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal
C and Heymann D: Interleukin-34 promotes tumor progression and
metastatic process in osteosarcoma through induction of
angiogenesis and macrophage recruitment. Int J Cancer. 137:73–85.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu JQ, Bai X, Duan DC and Dou AX: Role of
five small nucleotide polymorphisms in the VEGF gene on the
susceptibility to osteosarcoma and overall survival of patients.
Oncol Lett. 10:1481–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Autiero M, Waltenberger J, Communi D,
Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M,
Bono F, et al: Role of PlGF in the intra- and intermolecular cross
talk between the VEGF receptors Flt1 and Flk1. Nat Med. 9:936–943.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ribatti D: The discovery of the placental
growth factor and its role in angiogenesis: A historical review.
Angiogenesis. 11:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fischer C, Jonckx B, Mazzone M, Zacchigna
S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M,
De Mol M, et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor
resistant tumors without affecting healthy vessels. Cell.
131:463–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meng FJ, Xiao SX, Zhang Y, Wang W, Wang B
and Fan XY: Prognostic significance of placenta growth factor
expression in patients with multiple cancers: A meta-analysis. Int
J Clin Exp Med. 8:12726–12735. 2015.PubMed/NCBI
|
|
33
|
Taylor AP and Goldenberg DM: Role of
placenta growth factor in malignancy and evidence that an
antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis
of human breast cancer xenografts. Mol Cancer Ther. 6:524–531.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Clover J and Gowen M: Are MG-63 and HOS
TE85 human osteosarcoma cell lines representative models of the
osteoblastic phenotype? Bone. 15:585–591. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fogh J, Wright WC and Loveless JD: Absence
of HeLa cell contamination in 169 cell lines derived from human
tumors. J Natl Cancer Inst. 58:209–214. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pontén J and Saksela E: Two established in
vitro cell lines from human mesenchymal tumours. Int J Cancer.
2:434–447. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lisignoli G, Toneguzzi S, Cattini L, Pozzi
C and Facchini A: Different expression pattern of cytokine
receptors by human osteosarcoma cell lines. Int J Oncol.
12:899–903. 1998.PubMed/NCBI
|
|
38
|
Cifuentes M, García MA, Arrabal PM,
Martínez F, Yañez MJ, Jara N, Weil B, Domínguez D, Medina RA and
Nualart F: Insulin regulates GLUT1-mediated glucose transport in
MG-63 human osteosarcoma cells. J Cell Physiol. 226:1425–1432.
2011. View Article : Google Scholar : PubMed/NCBI
|
